Physician profile
William Schafer
NPI 1932107174
$3,261.25
in general payments reported to CMS, 2019-2025
19 companies · $17.16 in 2025
The $17.16 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $627 · 2020: $573 · 2021: $431 · 2022: $828 · 2023: $238 · 2024: $547 · 2025: $17.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $802.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $786.38 | 2020-2024 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $466.45 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $310.22 | 2021-2023 | Farxiga |
| Amarin Pharma, INC. | $233.46 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $213.08 | 2022-2024 | Camzyos |
| Amgen INC. | $210.02 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $166.35 | 2019-2022 | |
| Boston Scientific Corporation | $164.66 | 2022 | |
| Merck Sharp & Dohme LLC | $163.84 | 2021-2023 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.52 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.01 | 2024 | |
| Lilly USA, LLC | $82.65 | 2019 | |
| Abbott Laboratories | $64.12 | 2019-2024 | Aveir |
| Lexicon Pharmaceuticals, INC. | $45.47 | 2023-2024 | Inpefa |
| Kestra Medical Technology Services, INC. | $36.50 | 2023 | Assure Wcd |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $24.82 | 2021-2022 | |
| Bardy Diagnostics, INC. | $15.00 | 2020 | |
| Sanofi-Aventis U.S. LLC | $10.95 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $8.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Schafer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.